Joe Keegan, Former CEO of Octet-Manufacturer ForteBio, Joins Nanomedical Diagnostics Board of Directors

Dr. Keegan to provide expertise in the label-free detection market as the company expands sales of AGILE R100, its benchtop biosensor assay for lead optimization.

San Diego, CA

Nanomedical Diagnostics, a biotech company driving the use of label-free biosensor assays in life science research and diagnostics, appoints Dr. Joe Keegan to its Board of Directors. With over thirty years of experience working with cutting-edge, novel technologies, Dr. Keegan has a proven track record of developing early stage companies into successes in the life science market. Notably, Dr. Keegan led ForteBio, Inc., manufacturer of the Octet and Blitz lines of label-free detection systems, from $6MM in revenue in 2007 to $27MM in 2011, the year prior to its acquisition by Pall Life Sciences. Dr. Keegan also served as CEO of Molecular Devices Corporation from 1998 to 2007 where he grew revenue from $30MM to $185MM.

“We are thrilled to welcome Joe Keegan to our board and look forward to the wealth of proven bus

< | >